RAPP
Rapport Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.70B
P/E Ratio
—
EPS
$-3.00
Beta
—
52W High
$42.27
52W Low
$7.73
50-Day MA
$31.72
200-Day MA
$26.37
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc. is a pioneering biotechnology company dedicated to developing transformative therapeutics for neurodegenerative diseases, with a primary emphasis on Alzheimer's disease and related cognitive impairments. Utilizing its proprietary drug candidates and cutting-edge technology platforms, the firm is committed to advancing scientific research and achieving clinical validation. With a focus on addressing significant unmet medical needs, Rapport Therapeutics is strategically positioned to drive innovation in the neuroscience sector, offering promising solutions for patients facing debilitating cognitive challenges.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-124.08M |
| Operating Margin | 0.00% |
| Return on Equity | -28.20% |
| Return on Assets | -18.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $10.14 |
| Price-to-Book | 3.34 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $47.81M |
| Float | $31.24M |
| % Insiders | 4.66% |
| % Institutions | 107.54% |
Historical Volatility
HV 10-Day
43.04%
HV 20-Day
51.55%
HV 30-Day
59.76%
HV 60-Day
53.94%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($53.60 target)
1
Strong Buy9
BuyMore HEALTHCARE Stocks
Data last updated: 5/5/2026